Nanoring-based PARs reactivate & retarget the immune system without the cost or long-term risks of genetic modification.
No need for suicide genes or viral vectors. FDA-approved antibiotic Trimethoprim is all it takes to dissolve the CSANs (nanorings) and switch PARs off.
A cheaper, faster, more flexible and controllable way to deliver personalized oncolytic immunotherapy.
Showing promising early results in cancer oncology, CAR-T cell therapy genetically modifies a patient’s T-cells, reactivating and retargeting the immune system to kill tumor cells. As with most early-stage treatments, CAR-T therapy is complex and not without potential side effects—short- and long-term.
Tychon® introduces PARs®, which harnesses the power of protein dimerization to produce chemically self-assembling nanorings (CSANs). These nanorings form a stable, flexible construct to combine a patient’s T lymphocytes (T-cells) and a host of cancer-seeking antigens, creating a wide variety of adoptive cell therapies (PARs®) with selective anti-tumor capabilities.
+1 612 200 1039
227 Colfax Ave N, Ste 148 Minneapolis, MN 55405
©2015 Invenshure. all rights reserved.